Press releases
- Antengene To Present One Oral and Four Abstracts at ASCO 2024
- Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
- Antengene Presents Four Preclinical Posters at AACR 2024
- Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
- Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
- Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0765 |
---|---|
High | 0.0765 |
Low | 0.0765 |
Bid | 0.101 |
Offer | 0.114 |
Previous close | 0.0805 |
Average volume | 0.00 |
---|---|
Shares outstanding | 674.89m |
Free float | 360.15m |
P/E (TTM) | -- |
Market cap | 614.15m HKD |
EPS (TTM) | -1.02 HKD |
Data delayed at least 15 minutes, as of Jun 18 2024 07:02 BST.
More ▼